Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Haematologic Disease (Cancer)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT01298934
What this trial is testing

LBH589 (Panobinostat) for the Treatment of Myelofibrosis

Who this might be right for
Primary MyelofibrosisPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePost-Essential Thrombocythemia Related Myelofibrosis
Ronald Hoffman 22
Testing effectiveness (Phase 2)Looking for participantsNCT07154264
What this trial is testing

DZD8586 Combination in CLL/SLL (TAI-SHAN10)

Who this might be right for
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dizal Pharmaceuticals 66
Not applicableStudy completedNCT02080884
What this trial is testing

An Observational Study Examining the Effect of Added MabThera Therapy in Patients With Untreated Chronic Lymphocytic Leukemia

Who this might be right for
Chronic Lymphocytic Leukemia
Hoffmann-La Roche 150
Not applicableStudy completedNCT02158052
What this trial is testing

Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease

Who this might be right for
Multiple MyelomaAmyloidosis
Massachusetts General Hospital 2
Not applicableNo Longer AvailableNCT05269771
What this trial is testing

MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera

Who this might be right for
Polycythemia Vera
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)WithdrawnNCT04044209
What this trial is testing

The IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Who this might be right for
Myelodysplastic SyndromesAcute Myeloid Leukemia
Yale University
Testing effectiveness (Phase 2)Looking for participantsNCT06191263
What this trial is testing

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

Who this might be right for
Acute Myeloid Leukemia
Ryvu Therapeutics SA 98
Not applicableStudy completedNCT01653106
What this trial is testing

Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients

Who this might be right for
Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple Myeloma+1 more
Ohio State University Comprehensive Cancer Center 148
Not applicableLooking for participantsNCT05160584
What this trial is testing

Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Janssen Pharmaceutica N.V., Belgium 300
Very early researchLooking for participantsNCT06385652
What this trial is testing

PET Imaging Study of 68Ga-NB381 in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Peking University First Hospital 30
Early research (Phase 1)Looking for participantsNCT05945849
What this trial is testing

CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML

Who this might be right for
Leukemia, Myeloid, Acute
University of Pennsylvania 16
Testing effectiveness (Phase 2)Study completedNCT04992949
What this trial is testing

Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm

Who this might be right for
Acute Myeloid LeukemiaMyeloproliferative Syndrome
French Innovative Leukemia Organisation 42
Testing effectiveness (Phase 2)WithdrawnNCT06085638
What this trial is testing

Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

Who this might be right for
Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
Very early researchUnknownNCT04186052
What this trial is testing

Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma

Who this might be right for
Multiple Myeloma
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Not applicableNot Yet RecruitingNCT05440747
What this trial is testing

Treatment Free Remission (TFR) in CML Patients （CML-CP）Study

Who this might be right for
Chronic Myeloid LeukemiaTreatment-free Remission
Guangdong Provincial People's Hospital 203
Large-scale testing (Phase 3)Ended earlyNCT00109538
What this trial is testing

Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicMyelodysplasia+1 more
Merck Sharp & Dohme LLC 47
Not applicableStudy completedNCT07249138
What this trial is testing

Impact of Congenital Heart Disease on the Prognosis of Childhood Hematological Neoplasms: A Multicenter Cohort Study

Who this might be right for
Congenital Heart Disease (CHD)Hematologic Malignancy
Children's Hospital of Fudan University 800
Testing effectiveness (Phase 2)Active Not RecruitingNCT05656248
What this trial is testing

Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms

Who this might be right for
Myeloid Neoplasm
St. Jude Children's Research Hospital 25
Not applicableUnknownNCT06476535
What this trial is testing

Observatory of Patients With MyeloProliferative Neoplasm Treated With Anti-inflammatory Immunotherapy

Who this might be right for
Myeloproliferative NeoplasmInflammatory Disease
University Hospital, Brest 100
Early research (Phase 1)UnknownNCT03840317
What this trial is testing

Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia

Who this might be right for
Acute Lymphocytic Leukemia
Hebei Senlang Biotechnology Inc., Ltd. 20
Next Page